The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Predictive clinical outcome of the intratumoral CD66b‐positive neutrophil‐to‐CD8‐positive T‐cell ratio in patients with resectable nonsmall cell lung cancer
Open accessAbstract
BACKGROUND: The role of the interaction between tumor cells and inflammatory cells in nonsmall cell lung carcinoma (NSCLC) is unclear. In this study, the authors assessed the prognostic impact of intratumoral cluster of differentiation 66b (carcinoembryonic antigen‐related cell adhesion molecule 8 [CD66b])‐positive neutrophils and of the intratumoral CD66b‐positive neutrophil‐to‐cluster of differentiation 8 (cell surface antigen T8 [CD8])‐positive lymphocytes (the CD66b‐positive neutrophil‐to‐CD8‐positive lymphocyte ratio [iNTR]) in patients with resectable NSCLC. METHODS: Expression levels of CD66b and CD8 were evaluated by immunohistochemistry on tissue microarrays consisting of 632 NSCLC specimens from patients who underwent curative surgery. The relation between clinicopathologic variables and patient outcome was assessed. RESULTS: Intratumoral CD66b‐positive neutrophils were elevated in 318 patients (50%). In univariate analysis, an increase in CD66b‐positive cells was associated with a high cumulative incidence of relapse (CIR) (median CIR, 51 months for low CD66b‐positive cell density; 36 months for high CD66b‐positive cell density; P = .002) and trended toward worse overall survival (OS) (median OS, 57 months for low CD66b‐positive cell density; 54 months for high CD66b‐positive cell density; P = .088). The iNTR was elevated in 190 patients (30%). An increased iNTR was strongly associated with both a high CIR (median CIR: 43 months for an iNTR ≤1; 34 months for an iNTR >1; P < .0001) and poor OS (median OS: 60 months for an iNTR ≤1; 46 months for an iNTR >1; P < .0001). In multivariate analysis, independent prognostic factors for a higher CIR were high iNTR (hazard ratio [HR], 0.71; 95% confidence interval [CI], 0.56‐0.90; P = .005) and tumor stage >I, (HR, 0.39; 95% CI, 0.30‐0.52; P < .0001). Independent prognostic factors for worse OS were a high iNTR (HR, 0.70; 95% CI, 0.54‐0.91; P = .007) and tumor stage >I (HR, 0.35; 95% CI, 0.26‐0.47; P < .0001). CONCLUSIONS: The current results indicated that the iNTR is a novel, independent prognostic factor for a high rate of disease recurrence and poor OS in patients with resectable NSCLC. Cancer 2011;. © 2011 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
The tumor microenvironment and its role in promoting tumor growth
Whiteside, T. L. (2008) · Oncogene · doi:10.1038/onc.2008.271 · Cited by 2,376
The role of myeloid cells in the promotion of tumour angiogenesis
Murdoch, C., Muthana, M., Coffelt, S. B., & Lewis, C. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2444 · Cited by 1,642
ROS-Generating Mitochondrial DNA Mutations Can Regulate Tumor Cell Metastasis
Ishikawa, K., Takenaga, K., Akimoto, M., Koshikawa, N., Yamaguchi, A., Imanishi, H., Nakada, K., Honma, Y., & Hayashi, J.-I. (2008) · Science · doi:10.1126/science.1156906 · Cited by 1,444
TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression
Yang, L., Pang, Y., & Moses, H. L. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.04.002 · Cited by 1,023
The polarization of immune cells in the tumour environment by TGFβ
Flavell, R. A., Sanjabi, S., Wrzesinski, S. H., & Licona-Limón, P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2808 · Cited by 940
Biological reactivity and biomarkers of the neutrophil oxidant, hypochlorous acid
Winterbourn, C. C. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00286-x · Cited by 247
Cited by
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Hendry, S., Salgado, R., Gevaert, T., Russell, P. A., John, T., Thapa, B., Christie, M., van de Vijver, K., Estrada, M. V., Gonzalez-Ericsson, P. I., et al. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000161 · Cited by 799
Neutrophils in the tumor microenvironment
Powell, D. R., & Huttenlocher, A. (2016) · Trends in Immunology · doi:10.1016/j.it.2015.11.008 · Cited by 578
Bremnes, R. M., Busund, L.-T., Kilvær, T. L., Andersen, S., Richardsen, E., Paulsen, E. E., Hald, S., Khanehkenari, M. R., Cooper, W. A., Kao, S. C., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.01.015 · Cited by 502
Singhal, S., Bhojnagarwala, P. S., O'Brien, S., Moon, E. K., Garfall, A. L., Rao, A. S., Quatromoni, J. G., Stephen, T. L., Litzky, L., Deshpande, C., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.001 · Cited by 478
Metadata
- Authors
- Ilie, M., Hofman, V., Ortholan, C., Bonnetaud, C., Coëlle, C., Mouroux, J., & Hofman, P.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2011-08-25
- Volume
- 118
- Issue
- 6
- Pages
- 1726-1737
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2003268223
- Cited by
- 179
- References
- 8
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Predictive clinical outcome of the intratumoral CD66b‐positive neutrophil‐to‐CD8‐positive T‐cell ratio in patients with resectable nonsmall cell lung cancer. https://app.cochat.ai/papers/10.1002/cncr.26456
- The paper
- Ilie, M., Hofman, V., Ortholan, C., Bonnetaud, C., Coëlle, C., Mouroux, J., & Hofman, P. (2012). Predictive clinical outcome of the intratumoral CD66b‐positive neutrophil‐to‐CD8‐positive T‐cell ratio in patients with resectable nonsmall cell lung cancer. Cancer. https://doi.org/10.1002/cncr.26456
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.